Pharmafile Logo

Graduation day is celebrated by Lucid’s third Futures Academy cohort

- PMLiVE

Lucid’s Futures Academy is proud to release its most recent cohort of graduates into the business for the first of their two rotations.

The Futures Academy begins with an eight-week intensive course, aimed at equipping graduates with the skills needed for their careers in either account management or medical writing. The course, which began in January, covered a wide variety of topics, from general education about the pharmaceutical industry and its regulatory environment, to more specific tools for account management, medical writing and brand planning.

Elizabeth Hunt, one of this year’s cohort commented, “I think one great, and quite unique, aspect of the programme is the opportunity to see what is involved in both writing and accounts. A lot of people’s preferences change during their placements, so to have the chance to try both is really special and reflects Lucid’s willingness to make your job fit with you and your passions.”

Charlotte Monnickendam, another of this year’s graduates also said, “The programme gave us exposure to some of the industry’s finest people. From hiring external pharmaceutical marketing experts to spending valuable time with some of Lucid’s leaders. We are now in a good position to hone our skills to pursue our desired careers.”

The Futures Academy illustrates Lucid’s continual investment in bringing new talent to the industry. The programme reflects the human-centric spirit of the Lucid Group – individuals and teams working together to help nurture and build talent.

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD